# DRUG AMORPHOUS SOLID DISPERSIONS USING MESOPOROUS SILICA PARTICLES -FORMULATION APPROACHES AND PROCESS SCALE-UP

Marek Šoltys<sup>1,2</sup>, Jakub Mužík<sup>1</sup>, David Zůza<sup>1</sup>, Tereza Boleslavská<sup>1,2</sup>, Sarah Akhlasová<sup>1</sup>, Martin Balouch<sup>1</sup>, Pavel Kovačík<sup>2</sup>, Josef Beránek<sup>2</sup>, František Štěpánek<sup>1</sup>

<sup>1</sup>University of Chemistry and Technology in Prague, Department of Chemical Engineering, Technická 5, 16628 Prague 6, Czech Republic, stepanef@vscht.cz; <sup>2</sup> Zentiva, k.s., U Kabelovny 130, 10237 Prague 10



Drying

Pharmaceutical **Applied Research** Center

Parc

Scan QR codes for article links



# Why drugs in porous particles?

• Drugs (APIs) loaded inside the pores stay amorphous • Max pore size is 20x the diameter of API molecule • Amorphous state provides faster dissolution rates • Oral formulation option for BCS class II and IV APIs

• Mesoporous particles enhance disintegrant efficiency

## There are several methods of loading APIs into porous particles

Solvent immersion (adsorption equilibrium) when API is at least sparingly soluble in low polar solvents or soluble in more polar solvents, lowest crystallinity 

#### **Solvent evaporation / incipient wettnes**

when API is at least sparingly soluble in any volatile solvent, higher loadings, risk of crystallization at very high loading

#### **API melt loading**

when API degrades above the melting point, solvent free - for insoluble APIs, risk of partial crystallinity



## Silica particles and their scale-up

Nano particles (SiNano)

TEOS + CTAB in  $H_2O$  + EtOH mix

- reaction initiated by ammonia

c<sub>CTAB</sub> and c<sub>EtOH</sub> affects the shell thickness and porosity 600 d.nm, 1040 m<sup>2</sup>/g, 0.6-0.8 cm<sup>3</sup>/g, pores 2-3 nm 40 fold volume based scale-up achieved - 4g / batch



PSDs and N2 adsorption isotherms of silica nano-particles from original synthesis and from scale-up

TEM image of silica nano-particles prepared using the original synthesis and visualisation of CFD model used for scale-up development

Chem. Eng. J. 334, 1135-



weak acid

neutral

weak base

weak acid

weak acid

neutral

neutral

neutral

weak base

weak base

weak base



achieved loading [w<sub>API</sub>/w<sub>silica</sub>]

(from solution of [mg/ml])

**25 %** (DCM 20), **41 %** (MeOH 65)

43 % (DCM 20)

**39 %** (H<sub>2</sub>O 32), **83 %** (H<sub>2</sub>O 64)

**35 %** (DCM 20), **14 %** (MeOH 64)

6 % (Isopropanol 5)

**5** % (Acetone 20), **10** % (Acetone 44)

**18 %** (MeOH 64)

**28 %** (CHCl<sub>3</sub> 10), **32 %** (CHCl<sub>3</sub> 20)

**52 %** (DCM 10), **45 %** (DCM 20)

**5** % (MeOH 10), **11** % (MeOH 20),

**36 %** (CHCl<sub>3</sub> 7.5)

**27 %** (CHCl<sub>3</sub> 12.5)

all samples with SiNano

10 20 30 40 50 60

Time (min)

www.theparc.eu

www.vscht.cz

www.chobotix.cz



Sorption



Loading solutions concentration was altered to achieve 2, 5, 10 and 20 % loadings in 1 cycle. Higher loadings (>20 %) were achieved using multiple cycles.

Fast diss. APIs: **Highest non-crystalline loading** [W<sub>API</sub>/W<sub>silica</sub>] 60 % (Si-Micro, SLC500), Ibuprofen **40 %** (Si-Nano), **20 %** (Syl72FP) **40 %** (Si-Micro) Lacosamide Slow diss. APIs: Valsartan **60 %** (Si-Micro)



Ibuprofen loaded into silica microparticles using heated fluidized bed.

Mixture of Ibuprofen crystals and aggregates (<100  $\mu$ m) of SiMicro at 30, 40 and 50% IBU content, fluidized for 2, 5 and 10 minutes.

#### Suitable for industrial scale-up.





Maximum achievable loading with complete amorphization was **40%** of ibuprofen when fluidized for 10 min.

The loading depends on:

**Fast dissolving APIs:** 

Ibuprofen

Lacosamide

Abacavir sulphate

**Slow dissolving APIs:** 

Valsartan

API\_SA

Ezetimibe

API\_SN1

API\_SN2

Amlodipine

Aprepitant

API\_SB

### Micro particles (SiMicro)

TEOS + Octylamine (1:1 v/v)- reaction initiated by water + EtOH (3:1 v/v) formation of micro-spheres with hierarchical mesoporous Micropor. Mesopor. network, 10-70 μm, 980 m<sup>2</sup>/g, 0.8 cm<sup>3</sup>/g, 6-10 nm Mater, 274, 61-69 (2019) production of 10 g / batch achieved

![](_page_0_Figure_42.jpeg)

PSD and N2 adsorption isotherm of silica Scheme, SEM and TEM image of the micromicro-particles with hierarchical porous particles. structure

**Chosen commercial silica excipients** Merck Parteck<sup>®</sup> SLC 500 Grace Syloid ® 72 FP 13  $\mu$ m, 510 m<sup>2</sup>/g, 0.8 cm<sup>3</sup>/g, 2-20 nm 6  $\mu$ m, 340 m<sup>2</sup>/g, 1.1 cm<sup>3</sup>/g, 5-60 nm

![](_page_0_Figure_45.jpeg)

solution concentration, and solvent polarity...

![](_page_0_Figure_47.jpeg)

![](_page_0_Figure_48.jpeg)

![](_page_0_Figure_49.jpeg)

## Acknowledgement

M.S. would like to thank prof. Pavel Ulbrich for TEM images and Dr. Miloslav Lhotka for N<sub>2</sub> sorption measurements. The financial support from the Specific University Research (MSMT), of the Czech Science Foundation (project No. GACR 19-26127X) and of Zentiva is gratefully acknowledged.

![](_page_0_Picture_52.jpeg)

![](_page_0_Picture_53.jpeg)

![](_page_0_Figure_54.jpeg)

Increased dissolution rate remains With too high recrystallisation of even with high evaporation loadings the API the dissolution improvement is lost

## **Determination of loading by corrected TGA**

Simultaneous evaporation of  $H_2O_1$ , silanol groups and API

1) TGA measurement, 2) Derivation of TG **3)** Baseline of the API evaporation valley in dTG **4)** Subtraction of the baseline from dTG 5) Reconstruction of TG from the corrected dTG

# the 778 cm<sup>-1</sup> band in the amorphised samples. 20 30 40 50 time (min)

Wavenumbers (cm<sup>-1</sup>)

Amorphisation observable on FT-IR as well through the absence of

1700

1500

![](_page_0_Figure_60.jpeg)

## or by transmission FT-IR using KBr pellets

200 mg of dry KBr + 1-2 mg of silica containing API - pressed into pellets Ratio of API band area vs. silica band area plotted for various API contents

![](_page_0_Figure_63.jpeg)